iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Disclosure of Correction of Immaterial Error (Tables)

Disclosure of Correction of Immaterial Error (Tables)

3 Months Ended

Sep. 30, 2021

Disclosure of Correction of Immaterial Error [Abstract]

Schedule of Reclassifications and Error Corrections

The reclassifications did not have any impact to consolidated operating income (loss), net income (loss), cash flows or earnings per share. The following tables illustrate the reclassifications and financial impact on the various line items impacted on the Condensed Consolidated Statement of Operations and Segment Reporting, as follows:


Statement of Operations Reclassifications
	Three Months Ended
(In thousands)	September 30, 2020
Operating expense:	As Reported		Adjustment		As Revised		% Change
Cost of goods sold	$	—	$	107	$	107	100	%
Research and development		1,762		100		1,862	6	%
General and administrative		5,572		(207)		5,365	(4)	%
Total operating expenses	$	7,334			$	7,334


Segment Reporting Reclassifications

As Reported:
For the Three Months Ended September 30, 2020 (in thousands)	iBio, Inc.		iBio CDMO		Eliminations		Total
Cost of goods sold	$	—	$	—	$	—	$	—
Research and development		342		1,638		(218)		1,762
General and administrative		2,672		3,130		(230)		5,572

As Revised:
For the Three Months Ended September 30, 2020 (in thousands)	iBio, Inc.		iBio CDMO		Eliminations		Total
Cost of goods sold	$	54	$	53	$	—	$	107
Research and development		235		1,845		(218)		1,862
General and administrative		2,672		2,923		(230)		5,365